English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduDiscovering a new immunotherapy for metastatic breast cancer
Despite new and emerging immunotherapies, there is still no answer for breast cancer. Alana Welm, PhD, senior director of basic science at Huntsman Cancer Institute and professor of oncological sciences at the University of Utah(the U), recently received grants from the Breast Cancer Research Foundation and the Susan G. Komen Foundation to try and find that answer. Welm and her team discovered a protein called RON kinase that regulates an immune response to tumors. When taking RON kinase away in mice, the immune system was activated and attacked the cancer. This research opens the door to finding a medication that helps the immune system eliminate breast cancer.
Providing risk prevention to emerging adults in rural areas
The National Cancer Institute recently awarded a grant to cancer centers and hospitals serving the four corners region of the United States. Deanna Kepka, PhD, MPH, David Wetter, PhD, and Echo Warner, PhD, MPH, along with researchers from the University of New Mexico Comprehensive Cancer Center, the University of Arizona Cancer Center, and the University of Colorado Cancer Center, will teach young adults, ages 18-26, about cancer risks through social media. David Buller, PhD, researcher from Klein Buendell in Colorado, and Andrew Sussman, PhD, associate director for community outreach and engagement at the University of New Mexico Cancer Center, are the main principle investigators. The campaign will target young adults in rural counties, and inform them of risk factors like infrequent physical activity, an unhealthy diet, nicotine use, alcohol intake, ultraviolet radiation exposure, and resistance to the HPV vaccine. The team aims to teach them on Facebook, utilizing private groups to find emerging trends and personalize content.
Understanding how benign lung tumors can transform into cancer
Martin McMahon, PhD, senior director for preclinical research and co-leader of the experimental therapeutics program at Huntsman Cancer Institute and dermatology professor at the U, leads a team that has discovered how normal lung cells turn cancerous. The study, spanning 13 years of research and an extensive group of international collaborators, is published in Cancer Research. BRAFV600E is a subtype of human lung cancer. However, when BRAFV600E is expressed in normal lung cells of mice, it promotes only the growth of small, non-malignant tumors, which rarely progress to lung cancer. Because of this, McMahon and his team became interested in finding the genes that turned these tumors cancerous. To do so, they used a technique called Sleeping Beauty Transposon Mutagenesis to turn certain genes on and off in mice. This allowed McMahon and colleagues to identify a sizable panel of genes that, in combination with BRAFV600E, drives the progression of malignant lung cancer.
Nurses create an algorithm to monitor and prevent pneumonia in multiple myeloma patients
Low white blood cell counts caused by cancers or treatments that affect bone marrow, like multiple myeloma, puts patients at risk of getting pneumocystis jirovecii pneumonia (PJP). PJP is a fungal infection that develops in the lungs and most commonly affects immunocompromised cancer patients. Previously, nurses tracked patients individually to determine who needed more care. When Carrie Bellerive, BSN, RN, BMTCN, and her team noticed unexpected PJP infections, they collaborated with the multiple myeloma care team and built an algorithm to accurately determine which patients were at highest risk and needed intervention.
Scientists discover the link between inflammatory and blood vessel development biomarkers and distress in colorectal cancer patients
Psychological distress is common in patients who have colorectal cancer. In a study published in the journal Cancer Epidemiology, Biomarkers & Prevention, Clara Lindley, an undergraduate student, and Jennifer Ose, PhD, researcher at Huntsman Cancer Institute, found biomarkers within the blood linked to stress. In partnership with the University of Heidelberg in Germany, Lindley and Ose found an increase in biomarker concentrations was associated with future risk of distress in colorectal cancer patients 12 months after their surgery. This is one of the first studies to investigate this relationship in prospectively followed patients with colorectal cancer.
About Huntsman Cancer Institute at the University of Utah
Huntsman Cancer Institute at the U is the official cancer center of Utah and the only National Cancer Institute-designated Comprehensive Cancer Center in the Mountain West. The campus includes a state-of-the-art cancer specialty hospital and two buildings dedicated to cancer research. Huntsman Cancer Institute provides patient care, cancer screening, and education at community clinics and affiliate hospitals throughout the Mountain West. It is consistently recognized among the best cancer hospitals in the country by U.S. News and World Report. The region’s first proton therapy center opened in 2021 and a major hospital expansion is underway. Huntsman Cancer Institute is committed to creating a diverse and inclusive environment for staff, students, patients, and communities. Advancing cancer research discoveries and treatments to meet the needs of patients who live far away from a major medical center is a unique focus. More genes for inherited cancers have been discovered at Huntsman Cancer Institute than at any other cancer center, including genes responsible for breast, ovarian, colon, head and neck cancers, and melanoma. Huntsman Cancer Institute was founded by Jon M. and Karen Huntsman.
